{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:02:29Z","timestamp":1792839749509,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:00:00Z","timestamp":1705795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:00:00Z","timestamp":1705795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["The \"Center of Excellence for Metabolic Associated Fatty Liver Disease"],"award-info":[{"award-number":["The \"Center of Excellence for Metabolic Associated Fatty Liver Disease"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["National Sun Yat-sen University"],"award-info":[{"award-number":["National Sun Yat-sen University"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010002","name":"Ministry of Education","doi-asserted-by":"publisher","award":["Kaohsiung\" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project"],"award-info":[{"award-number":["Kaohsiung\" from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project"]}],"id":[{"id":"10.13039\/100010002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taiwan Association for the Study of the Liver"},{"name":"TASL Foundation"},{"DOI":"10.13039\/501100013460","name":"Taiwan Liver Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013460","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["MOST 109-2314-B-037-044"],"award-info":[{"award-number":["MOST 109-2314-B-037-044"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-K1110002"],"award-info":[{"award-number":["KMU-K1110002"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["MOST 108-2314-B-037-066-MY3"],"award-info":[{"award-number":["MOST 108-2314-B-037-066-MY3"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-TC108B06"],"award-info":[{"award-number":["KMU-TC108B06"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-TC108B07"],"award-info":[{"award-number":["KMU-TC108B07"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-DK109002"],"award-info":[{"award-number":["KMU-DK109002"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["105KMUOR08"],"award-info":[{"award-number":["105KMUOR08"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-TC109B05"],"award-info":[{"award-number":["KMU-TC109B05"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH109-9R06"],"award-info":[{"award-number":["KMUH109-9R06"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH109-9R05"],"award-info":[{"award-number":["KMUH109-9R05"]}]},{"name":"Kaohsiung Medical University Hospital","award":["MOHW109-TDU-B-212-114006"],"award-info":[{"award-number":["MOHW109-TDU-B-212-114006"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH-IIT-109-2-05"],"award-info":[{"award-number":["KMUH-IIT-109-2-05"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMHK-DK(C)111004"],"award-info":[{"award-number":["KMHK-DK(C)111004"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMHK-DK(C)111006"],"award-info":[{"award-number":["KMHK-DK(C)111006"]}]},{"name":"Gilead Hong Kong Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Both European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases and the Infectious Diseases Society of America (AASLD-IDSA) guidelines recommend simplified hepatitis C virus (HCV) treatment with pan-genotypic sofosbuvir\/velpatasvir or glecaprevir\/pibrentasvir for eligible patients. This observational study used real-world data to assess these regimens\u2019 safety in eligible patients and develop an algorithm to identify patients suitable for simplified treatment by non-specialists.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>7,677 HCV-infected patients from Taiwan Hepatitis C Registry (TACR) who received at least one dose of sofosbuvir\/velpatasvir or glecaprevir\/pibrentasvir, and fulfilled the EASL\/AASLD-IDSA criteria for simplified treatment were analyzed. Multivariate analysis was conducted on patient characteristics and safety data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Overall, 92.8% (7,128\/7,677) of patients achieved sustained virological response and only 1.9% (146\/7,677) experienced Grades 2\u20134 laboratory abnormalities in key liver function parameters (alanine aminotransferase, aspartate aminotransferase, and total bilirubin), with only 18 patients (0.23%) experiencing Grades 3\u20134 abnormalities. Age\u2009&gt;\u200970\u00a0years old, presence of hepatocellular carcinoma, total bilirubin\u2009&gt;\u20091.2\u00a0mg\/dL, estimated glomerular filtration rate\u2009&lt;\u200960\u00a0mL\/min\/1.73\u00a0m<jats:sup>2<\/jats:sup>, and Fibrosis-4\u2009&gt;\u20093.25 were associated with higher risks of Grades 2\u20134 abnormalities. Patients with any of these had an odds of 4.53 times than that of those without in developing Grades 2\u20134 abnormalities (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Real-world data from Taiwan confirmed that simplified HCV treatment for eligible patients with pan-genotypic regimens is effective and well tolerated. The TACR algorithm, developed based on this study\u2019s results, can further identify patients who can be safely managed by non-specialist care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s12072-023-10609-7","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T18:01:43Z","timestamp":1705860103000},"page":"461-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan"],"prefix":"10.1007","volume":"18","author":[{"given":"Ming-Lung","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi\u2010Ming","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lein-Ray","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Tao","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Feng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chih","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chu","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Jong","family":"Bair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Jen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee-Fu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Lun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Ting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Chang","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzeng-Hue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Hsiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee-Won","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Lin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Chieh","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng\u2010Shun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Nan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Yuan","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jui-Ting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chih","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Yu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guei-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Xiong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Lun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Neng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Lang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ta-Ya","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih\u2010Lin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzong-Hsi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Te-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Horng","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Chieh","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2376-421X","authenticated-orcid":false,"given":"Wan-Long","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,21]]},"reference":[{"issue":"5 Suppl 3","key":"10609_CR1","first-page":"1","volume":"15","author":"DT Dieterich","year":"2019","unstructured":"Dieterich DT. A simplified algorithm for the management of hepatitis C infection. Gastroenterol Hepatol. 2019;15(5 Suppl 3):1\u201312","journal-title":"Gastroenterol Hepatol"},{"issue":"5","key":"10609_CR2","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","volume":"7","author":"The Polaris Observatory HCV Collaborators","year":"2022","unstructured":"The Polaris Observatory HCV Collaborators. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396\u2013415","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10609_CR3","unstructured":"World Health Organization. Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment and care for key populations, 2022"},{"issue":"2","key":"10609_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229143","volume":"15","author":"R Castro","year":"2020","unstructured":"Castro R, et al. Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis. PLoS ONE. 2020;15(2): e0229143","journal-title":"PLoS ONE"},{"issue":"4","key":"10609_CR5","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","volume":"9","author":"E Oru","year":"2021","unstructured":"Oru E, et al. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis. Lancet Glob Health. 2021;9(4):e431\u2013445","journal-title":"Lancet Glob Health"},{"issue":"1","key":"10609_CR6","first-page":"48","volume":"28","author":"S Majethia","year":"2022","unstructured":"Majethia S, et al. Economic impact of applying the AASLD-IDSA simplified treatment algorithm on the real-world management of hepatitis C. J Manag Care Spec Pharm. 2022;28(1):48\u201357","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"10609_CR7","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(21)00467-2","volume":"7","author":"MB Klein","year":"2022","unstructured":"Klein MB. Simplifying HCV treatment: a pathway to elimination and model for delivering health care to vulnerable populations. Lancet Gastroenterol Hepatol. 2022;7(4):277\u2013279","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10609_CR8","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. HCV guidance: Recommendations for testing, managing, and treating hepatitis C, 2021"},{"issue":"5","key":"10609_CR9","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C: Final update of the series(\u2606). J Hepatol. 2020;73(5):1170\u20131218","journal-title":"J Hepatol"},{"issue":"Suppl 9","key":"10609_CR10","doi-asserted-by":"publisher","first-page":"S745","DOI":"10.1093\/infdis\/jiaa534","volume":"222","author":"O Falade-Nwulia","year":"2020","unstructured":"Falade-Nwulia O, Sulkowski MS. Hepatitis C virus treatment: simplifying the simple and optimizing the difficult. J Infect Dis. 2020;222(Suppl 9):S745-757","journal-title":"J Infect Dis"},{"issue":"1","key":"10609_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40121-021-00576-7","volume":"11","author":"PN Cheng","year":"2022","unstructured":"Cheng PN, et al. Sofosbuvir\/velpatasvir for hepatitis C virus infection: real-world effectiveness and safety from a nationwide registry in Taiwan. Infect Dis Ther. 2022;11(1):485\u2013500","journal-title":"Infect Dis Ther"},{"issue":"1","key":"10609_CR12","doi-asserted-by":"publisher","first-page":"23473","DOI":"10.1038\/s41598-021-03006-3","volume":"11","author":"C-F Huang","year":"2021","unstructured":"Huang C-F, et al. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. Sci Rep. 2021;11(1):23473","journal-title":"Sci Rep"},{"issue":"13","key":"10609_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000690","volume":"94","author":"ML Yu","year":"2015","unstructured":"Yu ML, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: A nationwide survey in Taiwan. Medicine (Baltimore). 2015;94(13): e690","journal-title":"Medicine (Baltimore)"},{"key":"10609_CR14","unstructured":"Ministry of Health and Welfare. Health insurance opens Hepatitis C all oral new drug prescription to all departments, assisting Hepatitis C elimination. Available from: https:\/\/www.mohw.gov.tw\/cp-5022-64175-1.html"},{"issue":"11","key":"10609_CR15","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/imj.15037","volume":"51","author":"J Haridy","year":"2021","unstructured":"Haridy J, et al. Outcomes of community-based hepatitis C treatment by general practitioners and nurses in Australia through remote specialist consultation. Intern Med J. 2021;51(11):1927\u20131934","journal-title":"Intern Med J"},{"issue":"6","key":"10609_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/liv.14849","volume":"41","author":"CY Chen","year":"2021","unstructured":"Chen CY, et al. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. Liver Int. 2021;41(6):1265\u20131277","journal-title":"Liver Int"},{"issue":"6","key":"10609_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jfma.2020.04.003","volume":"119","author":"ML Yu","year":"2020","unstructured":"Yu ML, et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (I) general population. J Formos Med Assoc. 2020;119(6):1019\u20131040","journal-title":"J Formos Med Assoc"},{"issue":"7","key":"10609_CR18","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.jfma.2020.04.002","volume":"119","author":"ML Yu","year":"2020","unstructured":"Yu ML, et al. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. J Formos Med Assoc. 2020;119(7):1135\u20131157","journal-title":"J Formos Med Assoc"},{"key":"10609_CR19","unstructured":"National Health Insurance Administration of Taiwan. Hepatitis C all-oral new drug section. Available from: https:\/\/www.nhi.gov.tw\/Content_List.aspx?n=A4EFF6CD1C4891CA&topn=3FC7D09599D25979"},{"issue":"8","key":"10609_CR20","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.14309\/ajg.0000000000000606","volume":"115","author":"C-F Huang","year":"2020","unstructured":"Huang C-F, et al. Extrahepatic malignancy among patients with chronic hepatitis C after antiviral therapy: A real-world nationwide study on Taiwanese chronic hepatitis C cohort (T-COACH). Am J Gastroenterol. 2020;115(8):1226\u20131235","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10609_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey AS, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461\u2013470","journal-title":"Ann Intern Med"},{"issue":"10","key":"10609_CR22","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1093\/cid\/ciz022","volume":"69","author":"E Gane","year":"2019","unstructured":"Gane E, et al. Safety and pharmacokinetics of glecaprevir\/pibrentasvir in adults with chronic genotype 1\u20136 hepatitis C virus infections and compensated liver disease. Clin Infect Dis. 2019;69(10):1657\u20131664","journal-title":"Clin Infect Dis"},{"key":"10609_CR23","unstructured":"U.S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE) version 5.0. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"},{"issue":"5","key":"10609_CR24","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cgh.2021.07.037","volume":"20","author":"C-F Huang","year":"2022","unstructured":"Huang C-F, et al. Impact of sofosbuvir-based direct-acting antivirals on renal function in chronic hepatitis C patients with impaired renal function: A large cohort study from the nationwide HCV registry program (TACR). Clin Gastroenterol Hepatol. 2022;20(5):1151-1162.e6","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10609_CR25","doi-asserted-by":"publisher","first-page":"2840","DOI":"10.1093\/cid\/ciz1160","volume":"71","author":"E Ogawa","year":"2020","unstructured":"Ogawa E, et al. Hepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: A practice implication. Clin Infect Dis. 2020;71(11):2840\u20132848","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10609_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jhep.2020.01.027","volume":"73","author":"M-L Yeh","year":"2020","unstructured":"Yeh M-L, et al. Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection. J Hepatol. 2020;73(1):62\u201371","journal-title":"J Hepatol"},{"key":"10609_CR27","unstructured":"American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Simplified HCV treatment for treatment-naive adults without cirrhosis. Available from: https:\/\/www.hcvguidelines.org\/treatment-naive\/simplified-treatment"},{"key":"10609_CR28","doi-asserted-by":"crossref","unstructured":"Wan Z, et al. Reinfection rate of hepatitis C in HIV-1 positive men who have sex with men: A systematic review and meta-analysis. Front Public Health. 2022;10","DOI":"10.3389\/fpubh.2022.855989"},{"issue":"11","key":"10609_CR29","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.3390\/v13112294","volume":"13","author":"CM Hong","year":"2021","unstructured":"Hong CM, et al. Drug resistance profile and clinical features for hepatitis C patients experiencing DAA failure in Taiwan. Viruses. 2021;13(11):2294","journal-title":"Viruses"},{"issue":"5","key":"10609_CR30","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","volume":"157","author":"GN Ioannou","year":"2019","unstructured":"Ioannou GN, et al. Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology. 2019;157(5):1264-1278.e4","journal-title":"Gastroenterology"},{"issue":"2","key":"10609_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.18176\/resp.00033","volume":"23","author":"MA Simon","year":"2021","unstructured":"Simon MA, Rojo O, Ryan P. Patients\u2019 preferences for treatment with the new direct acting antiviral therapies for chronic hepatitis C virus infection. Rev Esp Sanid Penit. 2021;23(2):67\u201375","journal-title":"Rev Esp Sanid Penit"},{"issue":"9","key":"10609_CR32","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1007\/s12325-019-01012-6","volume":"36","author":"TM Welzel","year":"2019","unstructured":"Welzel TM, et al. Assessing patient preferences for treatment decisions for new direct acting antiviral (DAA) therapies for chronic hepatitis C virus infections. Adv Ther. 2019;36(9):2475\u20132486","journal-title":"Adv Ther"},{"issue":"3","key":"10609_CR33","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jfma.2023.01.011","volume":"122","author":"ML Yu","year":"2023","unstructured":"Yu ML, et al. TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes. J Formos Med Assoc. 2023;122(3):202\u2013220","journal-title":"J Formos Med Assoc"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10609-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10609-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T19:11:54Z","timestamp":1712949114000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10609-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,21]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10609"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10609-7","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,21]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CYP: advisory committee member for AbbVie, Bristol-Myers Squibb (BMS), Gilead, and Roche. MLY: research support (grant) from BMS, Gilead, Merck, and Roche diagnostics; consultant of AbbVie, BMS, Gilead, Roche, and Roche diagnostics; speaker of AbbVie, BMS, Eisai, Gilead, Roche and Roche diagnostics. WLC: advisory board member for AbbVie, BMS, Gilead, PharmaEssentia, Roche, and Vaccitech; speaker for AbbVie, BMS, Gilead, and Roche. Chi\u2010Ming Tai, Lein-Ray Mo, Hsing-Tao Kuo, Chung-Feng Huang, Kuo-Chih Tseng, Ching-Chu Lo, Ming-Jong Bair, Szu-Jen Wang, Jee-Fu Huang, Ming-Lun Yeh, Chun-Ting Chen, Ming-Chang Tsai, Chien-Wei Huang, Pei-Lun Lee, Tzeng-Hue Yang, Yi-Hsiang Huang, Lee-Won Chong, Chien-Lin Chen, Chi-Chieh Yang, Chao-Hung Hung, Sheng\u2010Shun Yang, Pin-Nan Cheng, Tsai-Yuan Hsieh, Jui-Ting Hu, Wen-Chih Wu, Chien-Yu Cheng, Guei-Ying Chen, Guo-Xiong Zhou, Wei-Lun Tsai, Chien-Neng Kao, Chih-Lang Lin, Chia-Chi Wang, Ta-Ya Lin, Chih\u2010Lin Lin, Wei-Wen Su, Tzong-Hsi Lee, Te-Sheng Chang, Chun-Jen Liu, Chia-Yen Dai, Chi-Yi Chen, Jia-Horng Kao, Han-Chieh Lin declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}}]}}